Common adverse reactions The most common adverse reactions (≥5% of patients) listed in the prescribing information include:1 Urinary tract infections Pneumonia Serious adverse reactions The serious adverse reactions listed in the prescribing information include:1 Arterial and venous thromboembolic events Ischemic events, including myocardial infarction and ischemic stroke Cardiac arrest Sudden deaths Use in a specific population It is not yet known if Ondexxya affects an unborn baby. The manufacturer makes no recommendation regarding use during pregnancy.1 For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.1 References 1. Full prescribing information [EMA]: Ondexxya (andexanet alfa) [PDF] Alexion Pharmaceuticals, May 3, 2018 2. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity Siegal DM, New England Journal of Medicine, Dec 17, 2015 3. European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya (coagulation factor Xa (recombinant), inactivated-zhzo), the First and Only Antidote for the Reversal of Factor Xa Inhibitors Portola Pharmaceuticals press release, April 26, 2019 4. U.S. FDA Approves Portola Pharmaceuticals’ Andexxa, First and Only Antidote for the Reversal of Factor Xa Inhibitors Portola Pharmaceuticals press release, May 3, 2018